Clinical trial
Octreotide Efficacy and Safety in First-line Acromegalic Patients
NCT00171886 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00171886 |
|---|---|
| Title | Octreotide Efficacy and Safety in First-line Acromegalic Patients |
| Official title | Octreotide Efficacy and Safety in First-line Acromegalic Patients |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Acromegaly |
| Intervention type | Drug |
| Interventions | Octreotide |
| Enrollment | 20 |
| Start date | Jul 1, 2002 |
| Primary completion | May 1, 2006 |
| Completion | May 1, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | Feb 24, 2017 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: